Marker associated with non-alcoholic steatohepatitis
AssigneeMochida Pharmaceutical Co., Ltd.
InventorsAyumi Sato, Tsuyoshi Harada, Takashi Yano, Yoko Wakabayashi
Life of this patent
Estimating the term…
Abstract
Disclosed is a novel NASH marker for use in a method for detecting NASH or evaluating the severity of NASH, which utilizes at least one factor selected from the group consisting of an IL-1 receptor antagonist, sCD40, HMGB1, sPLA2 group IIA and an sPLA2 activity as the marker. Also disclosed is a method for detecting NASH or evaluating the severity of NASH in a subject, which utilizes the marker.
Claims3
A method for detecting a non-alcoholic steatohepatitis (NASH) or evaluating seriousness thereof comprising:
- (A) measuring an amount and/or activity level of IL-1 receptor antagonist in a biological specimen from a subject as a marker by immunoassay;
- and
- (B) determining if said subject has NASH or evaluating seriousness thereof by comparing the measured value of step (A) with a cut off value, wherein the cut off value is the borderline between positive and negative of a disease, and the cut off value for said IL-1 receptor antagonist is 652 pg/mL.
A method for detecting a non-alcoholic steatohepatitis (NASH) or evaluating seriousness thereof comprising:
- (A) measuring an amount and/or activity level of sCD40 in a biological specimen from a subject as a marker by immunoassay;
- and
- (B) determining if said subject has NASH or evaluating seriousness thereof by comparing the measured value of step (A) with a cut off value, wherein the cut off value is the borderline between positive and negative of a disease, and the cut off value for said sCD40 is 17.2 pg/mL.
A method for detecting a non-alcoholic steatohepatitis (NASH) or evaluating seriousness thereof comprising:
- (A) measuring an amount and/or activity level of HMGB1 in a biological specimen from a subject as a marker by immunoassay;
- and
- (B) determining if said subject has NASH or evaluating seriousness thereof by comparing the measured value of step (A) with a cut off value, wherein the cut off value is the borderline between positive and negative of a disease, and the cut off value for said HMGB1 is 3.4 ng/mL.
Dependencies are inferred from the claim text.